Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Hemogenyx Pharmaceuticals PLC

HEMO.L ✓ COMPLIANTFree checks used up today ☆ Track — members

LSE · Healthcare · Biotechnology & Medical Research ·

UK Micro Cap Analyst: N/A

Last Close

$6.21

▲ +2.20%

Market Cap $42.91M · Vol 6.92K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$42.91M

Micro Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

N/A

YoY

RSI (14)

32.99

Momentum

Beta

1.58

vs Market

52W High

$23.57

75.18% below

52W Low

$4.75

28.31% above

Volume

6.92K

Avg 22.48K

P/B

28.91

Price-to-book

ROE

N/A

Return on equity

Free Float

70.58%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Hemogenyx Pharmaceuticals PLC (HEMO.L) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does HEMO.L pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+3.79%

-23.52%

-40.23%

-58.20%

YTD

-18.71%

-69.71%

-32.26%

-41.88%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-13,159,331.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-232.90% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	28.91
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	6.90M

Technical Indicators

50-Day SMA	$8.27
200-Day SMA	$10.06
RSI (14)	32.99
Beta	1.58
52-Week High	$23.57
52-Week Low	$4.75

Volume Today	6.92K
Avg Daily Volume (30D)	22.48K
Relative Volume	0.31x
Volatility (10D)	74.07
Volatility (30D)	63.65
Free Float	70.58%

Analyst Consensus

N/A

Current Price $6.21

Mean Target N/A

52W Low$4.75 52W High$23.57

Current

Target

$4.75 $23.57

Current Analyst target

· 0 analysts

Identifiers

ExchangeLSE

FIGIBBG00BDKH4C6

ISINGB00BQVXM815

CountryUK

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +1.49% ARGX.BR argenx SE +2.29% ARGX argenx SE +1.13% INSM Insmed Incorporated +1.14% 2269.HK WuXi Biologics (Cayman) Inc. +0.32%

Company Profile

Hemogenyx Pharmaceuticals plc is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of a suite of products to address problems associated with the treatment of blood disorders, such as cancers and autoimmune diseases, and viral infections. Its products include immunotherapy product candidates for the treatment of acute myeloid leukemia (AML) and other blood malignancies and patient conditioning for bone marrow transplantation (the CDX bi-specific antibody and CAR-T therapy), and a cell therapy product for BM/HSC transplantation (the Hu-PHEC). Its lead product, HG-CT-1, is a CAR-T cell therapy designed to treat relapsed or refractory acute myeloid leukemia (R/R AML), which is in a Phase I clinical trial. Its Chimeric Bait Receptor (CBR) is a versatile range of potential treatments based on the methodology of programming immune cells using a type of modifiable synthetic receptor to destroy viral pathogens.